Advanced search
Publication Cover
Bioengineered Volume 12, 2021 - Issue 1
Submit an article Journal homepage
1,301
Views
11
CrossRef citations to date
0
Altmetric
Research Paper

miR-148a-3p suppresses the progression of acute myeloid leukemia via targeting cyclin-dependent kinase 6 (CDK6)

Hong Zhoua Department of Hematology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaView further author information
,
Xiaofeng Jiab College of Life Sciences, China Jiliang University, Hangzhou, ChinaView further author information
,
Fan Yanga Department of Hematology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaView further author information
&
Pengfei Shia Department of Hematology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8888-3845View further author information
ORCID Icon
Pages 4508-4519 | Received 18 Jan 2021, Accepted 13 Jul 2021, Published online: 24 Jul 2021

References

  • Rogers HJ, Vardiman JW, Anastasi J, et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014;99(5):821–829.
  • Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
  • Estey EH. Acute myeloid leukemia: 2014 update on risk-stratification and management. Am J Hematol. 2014;89(11):1063–1081.
  • Antar A, Kharfan-Dabaja MA, Mahfouz R, et al. Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk. 2015;15(5):298–302.
  • Riva L, Luzi L, Pelicci PG. Genomics of acute myeloid leukemia: the next generation. Front Oncol. 2012;2:40.
  • Lee S, Jung JW, Park SB, et al. Histone deacetylase regulates high mobility group A2-targeting microRNAs in human cord blood-derived multipotent stem cell aging. Cell Mol Life Sci. 2011;68(2):325–336.
  • Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23(20):4051–4060.
  • Li Y, Deng X, Zeng X, et al. The role of mir-148a in cancer. J Cancer. 2016;7(10):1233–1241.
  • Ma W, Zhang X, Chai J, et al. Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma. Tumour Biol. 2014;35(12):12467–12472.
  • Zhu Y, Gu L, Li Y, et al. miR-148a inhibits colitis and colitis-associated tumorigenesis in mice. Cell Death Differ. 2017;24(12):2199–2209.
  • Song C, Yang J, Jiang R, et al. miR-148a-3p regulates proliferation and apoptosis of bovine muscle cells by targeting KLF6. J Cell Physiol. 2019;234(9):15742–15750.
  • Meng LH, Zhang H, Hayward L, et al. Tetrandrine induces early G1 arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G1-S–specific cyclin-dependent kinases and by inducing p53 and p21 Cip1. Cancer Res. 2004;64(24):9086–9092.
  • Chen MT, Dong L, Zhang XH, et al. ZFP36L1 promotes monocyte/macrophage differentiation by repressing CDK6. Sci Rep. 2015;5(1):16229.
  • Shen X, Xiong GL, Jing Y, et al. The protein kinase C agonist prostratin induces differentiation of human myeloid leukemia cells and enhances cellular differentiation by chemotherapeutic agents. Cancer Lett. 2015;356(2):686–696.
  • Schmoellerl J, Barbosa IAM, Eder T, et al. CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Blood. 2020;136(4):387–400.
  • Wang X, Liang Z, Xu X, et al. miR-148a-3p represses proliferation and EMT by establishing regulatory circuits between ERBB3/AKT2/c-myc and DNMT1 in bladder cancer. Cell Death Dis. 2016;7(12):e2503.
  • Song B, Du J, Song DF, et al. Dysregulation of NCAPG, KNL1, miR-148a-3p, miR-193b-3p, and miR-1179 may contribute to the progression of gastric cancer. Biol Res. 2018;51(1):44.
  • Wu T, Qu L, He G, et al. Regulation of laryngeal squamous cell cancer progression by the lncRNA H19/miR-148a-3p/DNMT1 axis. Oncotarget. 2016;7(10):11553–11566.
  • Man LM, Morris AL, Keng M. New therapeutic strategies in acute lymphocytic leukemia. Curr Hematol Malig Rep. 2017;12(3):197–206.
  • De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.
  • Yang JS, Li BJ, Lu HW, et al. Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol. 2015;36(4):3035–3042.
  • Jili S, Eryong L, Lijuan L, et al. RUNX3 inhibits laryngeal squamous cell carcinoma malignancy under the regulation of miR-148a-3p/DNMT1 axis. Cell Biochem Funct. 2016;34(8):597–605.
  • Malumbres M, Sotillo R, Santamaria D, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 2004;118(4):493–504.
  • Jena N, Sheng J, Hu JK, et al. CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia. Leukemia. 2016;30(5):1033–1043.
  • Uras IZ, Maurer B, Nebenfuehr S, et al. Therapeutic vulnerabilities in FLT3-Mutant AML unmasked by palbociclib. Int J Mol Sci. 2018;19(12):3987.
  • Kollmann K, Heller G, Schneckenleithner C, et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013;24(2):167–181.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.